New GC Column Provides Fast, High-Resolution Forensic Drug Testing

14 Oct 2008
Samantha Rosoman
Campaign Coordinator

Product news

Phenomenex Inc. introduces the Zebron ZB-Drug-1 column for GC analysis of drugs of abuse. The Zebron ZB-Drug-1 column is 50% faster than existing technologies and delivers improved resolution of target analytes. Zebron ZB-Drug-1 is a mid-polarity stationary phase that separates analytes from the common matrix interferences found in biological samples.

Many drugs of abuse are difficult to separate because they have similar structures. The versatile Zebron ZB-Drug-1 columns separate all common drugs of abuse, replacing the multiple tests required with other GC columns. Zebron’s unique deactivation procedure improves peak shape for acidic and basic drugs, enabling more accurate quantitation. These columns are durable with MS-certified bleed levels that increase detection limits.

“Phenomenex is the GC market leader in forensic toxicology and we are the largest column supplier to the major labs in this industry,” commented Sky Countryman, Product Manager for Phenomenex. “We are pleased to meet the market’s need for increased analysis speed with these new columns.”

Links

Tags

Gas ChromatographyGas chromatography (GC) is an analytical technique used to separate and quantitate mixtures of small and volatile compounds. Gas chromatographs or GC systems include components such as GC columns, detectors, pumps and autosamplers. Choose from packed or capillary GC columns, flame ionization (FID), photoionization (PID) electron capture detectors and selective or non-selective detectors. Find the best gas chromatographs in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.